An international group of three scientists are the recipients of United States Pharmacopeial Convention’s 2014–2015 Global Fellowship Awards, aimed at advancing research involving quality standards for medicines.
An international group of three scientists are the recipients of United States Pharmacopeial Convention’s 2014–2015 Global Fellowship Awards, aimed at advancing research involving quality standards for medicines. The recipients’ research will involve analytical tools useful in researching the safety of biopharmaceutical drugs, the detection of substandard drugs in the developing world, and the quality of dry powder inhaler products.
Each of the following students has received a $30,000 USP Global Fellowship Award for the 2014–2015 academic year:
Khaja Muneeruddin, PhD candidate, University of Massachusetts-AmherstArea of research: New mass spectrometry-based methods to characterize highly heterogeneous biopharmaceuticals
This project includes the development of novel analytical tools to characterize the natural diversity of biopharmaceutics, contributing to the safety of biopharmaceutical drugs. The methods developed under the guidance of Dr. Igor Kaltrashov, director of the chemistry department, will allow for thorough characterization of biopharmaceutical drugs to detect heterogeneity, which, in certain cases, affects their therapeutic activity.
Nicholas M. Myers, PhD candidate, University of Notre DameArea of research: Paper-based iodometric titration for quantification of antibiotics
This research is related to the Paper Analytical Device (PAD) project, which was primarily developed to test for counterfeit medications in developing countries, but the technology has also been adapted for other uses, such as testing for iodine deficiency. Led by Dr. Marya Lieberman, associate professor of chemistry and biochemistry, the PAD project uses paper-based technologies to test for the presence of specific chemicals in various substances. This technology is especially useful in low-resource settings where sophisticated lab equipment may not be available.
Ahmed O. Shalash, PhD candidate, Alexandria University, EgyptArea of research: Investigation of performance descriptor(s) in carrier-based dry powder inhalers
The research deals with investigation of the role of carrier surface roughness. Under the supervision of professor of pharmacy Mohammed Khalafallah, the ultimate goal of the project is development of characterization techniques that express performance and are suitable for routine quality control of dry powder inhaler products. The possibility of replacing lactose with other carriers will also be studied.
Source: USP.org
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.